Radezolid

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Radezolid
Skeletal formula of radezolid
Clinical data
Routes of
administration
Intravenous infusion, oral
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H23FN6O3
Molar mass438.455 g/mol
3D model (JSmol)

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne.[1]

References[edit]

  1. ^ Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.

Further reading[edit]